Keywords
How to Cite
Abstract
The aim of the study is to analyze the dynamics of clinical, functional and psychoemotional parameters in patients with persistent and paroxysmal forms of atrial fibrillation. Materials and methods. The study involved 64 patients with persistent and paroxysmal atrial fibrillation (AF), divided into subgroups, depending on the method of treatment. To assess the course of AF performed tools and psychometric methods of studying the state of the cardiovascular system. Results. It was found that the addition of anxiolytic drug to the standard of care in patients with persistent AF more intensively eliminates the manifestations of rapid heartbeat, shortness of breath at rest, severe fatigue, sweating. In addition, a positive effect of treatment on electrocardiographic and echocardiographic parameters of the heart was found, which is confirmed statistically. During treatment, the score of stress and depressive symptoms was
significantly reduced in both groups of patients. A similar trend was observed in patients with paroxysmal AF with a significant difference in indicators before treatment, after treatment and after 1.5 months. Conclusion. Thus, additional administration of anxiolytics in patients with persistent and paroxysmal AF helped to reduce the clinical symptoms of AF, regression of left ventricular hypertrophy, improve intraventricular conduction processes, and increase the ejection fraction of the left ventricle and its reduction from high to low levels, as well as a score reduction in depression.
References
Belyuk NS, Snezhitsky VA. Risk factors for atrial fibrillation. Grodno Magazine state medical university. 2020;1:73-78.
Hindricks Gerhard, Potpara Tatjana, Dagres Nikolaos, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2020; 00:1-126.
Baranova EN. Atrial fibrillation in patients with hypertension. Arterial hypertension. 2011;4:293-304.
Conference. Atrial fibrillation and ventricular arrhythmias: practical implementation of modern recommendations for diagnosis and treatment. Health of Ukraine. 2016; 2(45):42-43.
Kopieva KV, Grakova EV. New markers of heart failure: significance for the diagnosis and prediction of NT-pro-BNP and interleukin receptors — members of the ST2 family. Complex problems of cardiovascular diseases. 2018;94-101.
Kivimaki M, Nyberg ST. Long working hour as a risk factor for atrial fibrillation: a multi-cohort study. Eur Heart J. 2017;38(34):2621-2628.
Chernyaeva MS, Petrova MM. Acute myocardial infarction and affective spectrum disorders. Siberian Medical Review. 2015;3:5-14.
Kryuchkova ON, Kostyukova EA. Assessment of the likelihood of comorbid pathology: cardiovascular disease and depression. Ulyanovsk Medical and Biological Journal. 2016;2:20-26.
Heijman J. Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance and Progression. Circ Res. 2014;114(9):1483-99.
Lampert R. ECG signatures of psychological stress. J Electrocardiol. 2015;48(6):1000-1005.
Filippova MO, Polunina OS. Predicting the development of atrial fibrillation paroxysm in patients with postinfarction cardiosclerosis. Kuban Scientific Medical Bulletin. 2017;24(3):114-119.
Shkolnikova MA, Kharlap MS. Genetically determined disorders. Russian journal of cardiology. 2011;1(87):8-25.
Lin YK, Chen YA. Aging Modulates the Substrate and Triggers Remodeling in Atrial Fibrillation. Circ J. 2017;14.
Svensson T, Kitlinski M. Psychological stress and risk of incident atrial fibrillation in men and women with known atrial fibrillation genetic risk scores. Scientific
Reports. 2017;7:1-8.
Goldovsky BM, Sid EV. The place of β-blockers in the complex therapy of persistent atrial fibrillation. Emergency medicine. 2014;6(61):88-92.